MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Dr Reddy's Laboratories Ltd-ADR

Затворен

СекторЗдравеопазване

13.24 0.61

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

13.01

Максимум

13.24

Ключови измерители

By Trading Economics

Приходи

1.5B

14B

Продажби

3.4B

84B

P/E

Средно за сектора

17.587

63.778

EPS

16.936

Дивидентна доходност

0.72

Марж на печалбата

16.795

Служители

27,048

EBITDA

2.4B

24B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+38.3% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.72%

2.39%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

8.8B

11B

Предишно отваряне

12.63

Предишно затваряне

13.24

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.06.2024 г., 13:33 ч. UTC

Придобивния, сливания и поглъщания

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update

26.06.2024 г., 12:32 ч. UTC

Придобивния, сливания и поглъщания

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million

25.04.2024 г., 10:32 ч. UTC

Печалби

Nestle India Reports Rise in Quarterly Profit, Announces JV With Dr. Reddy's Laboratories

23.01.2025 г., 17:46 ч. UTC

Печалби

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

23.01.2025 г., 17:42 ч. UTC

Печалби

Dr. Reddy's 3Q Rev INR83.59B

5.11.2024 г., 11:01 ч. UTC

Печалби

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

5.11.2024 г., 11:00 ч. UTC

Печалби

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

5.11.2024 г., 10:57 ч. UTC

Печалби

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

5.11.2024 г., 10:57 ч. UTC

Печалби

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

26.06.2024 г., 11:54 ч. UTC

Придобивния, сливания и поглъщания

Haleon: All Other 2024 Guidance Unchanged

26.06.2024 г., 11:54 ч. UTC

Придобивния, сливания и поглъщания

Haleon: Sale Will Dilute 2024 Rev by 0.5%, Adj Oper Pft by 1%

26.06.2024 г., 11:52 ч. UTC

Придобивния, сливания и поглъщания

Haleon: Sale Allow For NRT Exit Outside US, Trims Business Complexity

26.06.2024 г., 11:51 ч. UTC

Придобивния, сливания и поглъщания

Haleon: Deal Expected to Complete Early 4Q

26.06.2024 г., 11:50 ч. UTC

Придобивния, сливания и поглъщания

Haleon: Use of Proceeds Will Be in Line With Capital Allocation Priorities

26.06.2024 г., 11:49 ч. UTC

Придобивния, сливания и поглъщания

Haleon: Deal Structure Upfront Cash GBP458M, GBP42M Performance-Based Payable

26.06.2024 г., 11:48 ч. UTC

Придобивния, сливания и поглъщания

Haleon: Portfolio Includes Nicotinell, Nicabate, Habitrol and Thrive Available in Gum, Lozenge

26.06.2024 г., 11:47 ч. UTC

Придобивния, сливания и поглъщания

Haleon: Deal Worth GBP500M With Additional Proceeds From Inventory Transfer

26.06.2024 г., 11:46 ч. UTC

Придобивния, сливания и поглъщания

Haleon to Sell Non-US Nicotine Replacement Therapy Business to Dr. Reddy's Laboratories

7.05.2024 г., 10:56 ч. UTC

Печалби

Dr. Reddy's Laboratories 4Q Net INR13.07B Vs. Net INR9.59B >500124.BY

7.05.2024 г., 10:55 ч. UTC

Печалби

Dr. Reddy's Laboratories 4Q Rev INR70.83B Vs. INR62.97B >500124.BY

Сравнение с други в отрасъла

Ценова промяна

Dr Reddy's Laboratories Ltd-ADR Прогноза

Ценова цел

By TipRanks

38.3% нагоре

12-месечна прогноза

Среден 18.2 USD  38.3%

Висок 19.4 USD

Нисък 17 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Dr Reddy's Laboratories Ltd-ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

13.12 / 13.21Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.